未來世界金融(00572.HK)擬配售最多24.9億股 淨籌3310萬港元
格隆匯3月18日丨未來世界金融(00572.HK)發佈公告,2020年3月18日,配售代理中達證券投資與公司訂立配售協議,據此,公司擬透過配售代理配售最多24.9億股配售股份予不少於六名承配人,配售價為每股0.014港元。
配售股份最高數目佔公司現有已發行股本約19.95%,及經配售股份擴大後公司已發行股本約16.63%。配售事項下配售股份最高數目總面值將為249萬港元。配售價較股份基準價格折讓約19.54%。
待配售事項完成後,預期配售事項最高所得款項總額及所得款項淨額將分別約為3490萬港元及3310萬港元。按此基準,淨髮行價將約為每股配售股份0.0133港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.